BR112022005881A2 - Compostos de benzoxazinona como inibidores duplos de klk5/7 - Google Patents

Compostos de benzoxazinona como inibidores duplos de klk5/7

Info

Publication number
BR112022005881A2
BR112022005881A2 BR112022005881A BR112022005881A BR112022005881A2 BR 112022005881 A2 BR112022005881 A2 BR 112022005881A2 BR 112022005881 A BR112022005881 A BR 112022005881A BR 112022005881 A BR112022005881 A BR 112022005881A BR 112022005881 A2 BR112022005881 A2 BR 112022005881A2
Authority
BR
Brazil
Prior art keywords
klk5
compounds
dual inhibitors
benzoxazinone compounds
benzoxazinone
Prior art date
Application number
BR112022005881A
Other languages
English (en)
Portuguese (pt)
Inventor
Andreas Betz
Robert Zamboni
Original Assignee
Molecular Skin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Skin Therapeutics Inc filed Critical Molecular Skin Therapeutics Inc
Publication of BR112022005881A2 publication Critical patent/BR112022005881A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112022005881A 2019-10-01 2020-09-30 Compostos de benzoxazinona como inibidores duplos de klk5/7 BR112022005881A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962909006P 2019-10-01 2019-10-01
PCT/US2020/053369 WO2021067335A1 (en) 2019-10-01 2020-09-30 Benzoxazinone compounds as klk5/7 dual inhibitors

Publications (1)

Publication Number Publication Date
BR112022005881A2 true BR112022005881A2 (pt) 2022-06-21

Family

ID=75274622

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005881A BR112022005881A2 (pt) 2019-10-01 2020-09-30 Compostos de benzoxazinona como inibidores duplos de klk5/7

Country Status (12)

Country Link
US (2) US11643420B2 (https=)
EP (1) EP4037687B1 (https=)
JP (1) JP7854389B2 (https=)
KR (1) KR20220091488A (https=)
CN (1) CN114615984B (https=)
AU (1) AU2020359526A1 (https=)
BR (1) BR112022005881A2 (https=)
CA (1) CA3151626A1 (https=)
ES (1) ES3053975T3 (https=)
IL (1) IL291398B2 (https=)
MX (1) MX2022003929A (https=)
WO (1) WO2021067335A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
PH12022550646A1 (en) 2019-09-18 2023-04-03 Genentech Inc Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
ES3053975T3 (en) 2019-10-01 2026-01-28 Molecular Skin Therapeutics Inc Benzoxazinone compounds as klk5/7 dual inhibitors
TW202304890A (zh) * 2021-04-14 2023-02-01 美商百歐克斯製藥公司 Klk5雙環雜芳香族抑制劑

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
CA1309556C (en) * 1987-06-09 1992-10-27 Masayuki Kokubo 4h-3,1-benzoxazin-4-one compounds and pharmaceutical composition thereoffor the inhibition of serine proteases
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
DE4134770A1 (de) 1991-10-22 1993-04-29 Basf Ag Koernige bleichaktivatorzusammensetzung
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2184851A1 (en) 1996-09-05 1998-03-06 Cheng Chung Wu Method of manufacturing a microweavable flatware article made of synthetic material, the article produced thereby and an ink-imprinted film component for use in making the flatware article
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
PL343317A1 (en) * 1998-03-31 2001-08-13 Warner Lambert Co Benzoxazinones/benzothiazinones as serine protease inhibitors
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
SI1631295T1 (sl) 2003-06-06 2010-06-30 Arexis Ab Uporaba kondenziranih heterocikličnih spojin kotSCCE inhibitorjev za zdravljenje kožnih bolezni
SI3097085T1 (sl) 2014-01-23 2020-11-30 Sixera Pharma Ab Derivati benzoksazinona za zdravljenje kožnih bolezni
ES3053975T3 (en) 2019-10-01 2026-01-28 Molecular Skin Therapeutics Inc Benzoxazinone compounds as klk5/7 dual inhibitors

Also Published As

Publication number Publication date
CN114615984A (zh) 2022-06-10
TW202126631A (zh) 2021-07-16
JP7854389B2 (ja) 2026-05-01
US12281123B2 (en) 2025-04-22
IL291398B1 (en) 2025-01-01
ES3053975T3 (en) 2026-01-28
JP2022551583A (ja) 2022-12-12
AU2020359526A1 (en) 2022-04-21
IL291398A (en) 2022-05-01
US20210101911A1 (en) 2021-04-08
IL291398B2 (en) 2025-05-01
EP4037687B1 (en) 2025-10-29
MX2022003929A (es) 2022-06-14
WO2021067335A1 (en) 2021-04-08
CN114615984B (zh) 2025-02-07
CA3151626A1 (en) 2021-04-08
EP4037687A4 (en) 2023-09-27
EP4037687A1 (en) 2022-08-10
US20240067658A1 (en) 2024-02-29
US11643420B2 (en) 2023-05-09
KR20220091488A (ko) 2022-06-30

Similar Documents

Publication Publication Date Title
BR112022005881A2 (pt) Compostos de benzoxazinona como inibidores duplos de klk5/7
BR112023001957A2 (pt) Composições e métodos para inibir expressão de lpa
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
BR112023024551A2 (pt) Análogos de triazolo-pirimidina para tratamento de doenças relacionadas à inibição de recq helicase de síndrome de werner (wrn)
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
BR112022023271A2 (pt) Compostos
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
BR112018007381A2 (pt) compostos úteis como imunomoduladores
BR112017012327A2 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
MX2020013853A (es) Compuestos innovadores.
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112017004704A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
MX2019007873A (es) Terapia génica para tratar la enfermedad de wilson.
BR112022006242A2 (pt) Compostos aromáticos de arilmetileno como bloqueadores de canal do agitador de potássio kv1,3
BR112022020798A2 (pt) Compostos tricíclicos como inibidores de nlrp3
BR112017007782A2 (pt) agentes imunorreguladores
BR112017008809A2 (pt) agentes imunorreguladores
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
BR112021006319A2 (pt) compostos de indolinona para uso como inibidores de map4k1
BR112015019412A2 (pt) inibidores de bace1
BR112018013084A2 (pt) tratamentos de combinação compreendendo a administração de imidazopirazinonas
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
BR112017010599A2 (pt) análogos de ureia ligada substituída como moduladores sirtuin

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]